PRNewsWire
01 Jun 2026, 02:37 UTC · 15w ago
Verdict
Headline takes no side. We score ORIC +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Oricell's Ori-C101 achieved a 66.7% objective response rate (ORR) in late-line refractory hepatocellular carcinoma patients.
So whatThis is a massive improvement over the historical ORR of below 13% for this patient population, signaling high clinical efficacy and potential for market leadership.
More positive than 98% of claims this week
The Ori-C101 data from the registrational Phase Ib BEACON study has been selected for an oral presentation at the ASCO 2026 Annual Meeting.
So whatOral presentations at ASCO are high-visibility events that typically act as catalysts for biotech stock valuation and partnership interest.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 84% of claims this week
Oricell's Ori®OnGo platform has reduced ex vivo culture time to 3 days and vein-to-vein time to within 15 days.
More positive than 76% of claims this week
The company's AI-powered Ori®Ab platform has compressed the antibody discovery and screening cycle from 12 months to 3 months.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
The company reported highly positive clinical results for its lead CAR-T asset, achieving a 66.7% objective response rate in late-line HCC.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1d ago
+50.0%
Price agrees with the score
$12.68 vs $8.45 close before publication (May 29) · not market-adjusted
ORIC chart →
